European Diabetology
A COMPANY LIMITED BY GUARANTEE
TRUSTEES, REPORT
AND
UNAUDITED FINANCIAL STATEMENTS
For the year ended
31 August 2023
Company Registration No 08652560
Ch8rity No 1156725

European Diabetology
(A company limited by guarantee)
LEGAL ANDADMINISTRATIVE INFORMATION
TRUSTEES AND MANAGEMENT COMMIThEE
Prof M K Rutter (Chairl
Dr R Loos
Prof E Pearson
Prof B Ahren
S Tweddell
Prof K Gillespie
SECRETARY
M L Harris
COMPANY NUMBER
08652560
REGISTERED CHARITY NUMBER
11 $6725
REGISTERED OFFICE
2ND Floor
1 The Squ8re
Temple Quay
8nslol
8S16DG
PRINCIPAL OFFICE
Level 3
Learning & Re8earch Building
Soulhmead Ho8pilal
Soulhmead Road
Weslbury-On-Trym
Bristol
BS10 5NB
BANKERS
8arclays Bank PIC
15 Qugen Square
Bri8101
BS1 4NP
INDEPENDENT EK4MINER
RSM UK Tax and Accounting Limilgd
Chartered Accounlanls
Davidson House
Fgrbury Square
Reading
Berkshire
RG1 3EU

European Diabetology
(A company limited by guarantee)
TRUSTEES, REPORT
The Trustees present their report and unaudited financial statements for the year ended 31 August
2023.
The financial sl8lemenls have been prepared in accordance with the accounting polic1e3 sel out In the
note6 to the accounts and comply with the Companies Act 2006 and Accounting and Reporting by
Chafilies.. Statement of Recommended Practice applicable lo charities preparing their accounts in
accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland
IFRS1021 second edrtion - October 2019.
STRUCTURE, GOVERNANCE AND MANAGEMENT
European Diabetology is a company limited by guarantee (Company Rogislralion No 086525601 wrth
charitable slalus ICh8rily No 11567251. The company was registered with Companies House on 15
August 2013. The governing document of the organisalion is ils Memorandum and Arti¢l¢$ of
Association dated August 2013 and modified in March 2014.
The Trustees, who are also the directors for the purpose8 01 company law, who held office during I
yèar and up lo the dale of signature of the financial 81alemenl8 were 88 follows..
Prol M K Ruller
Dr R Loo8
Prof E Pe8rson
Prof B Ahren
S Tweddell
Prof K Gillespie
The day-lo-day management of the eharrty is carried out by thè Truslèas, who are appointed by a
resolution of the Trustees from a ￿ndIdate, or candidates, nominated in writing by the European
Association for the Study of Diabetes. The number ol Trustees shall not be les8 than three but shall not
be subject lo any maximum The Trustees hold olfice for three years and are then eligible for
r8appoinlmenl lor a further three years. Tha indu¢lign proces¥ for any newly appointed Trustee
corllprise8 an initial meeting with the Chairman and the Board, followed by a series of short meelin98
regarding power8 onLI responsibilities of the Trustee Board.
MEMBERS, LIABILITY
Exh member of the charitable company undertake5 to contribute lo the assets of the charitable
company in the event of il being wound up while they are a member, or within one year after they cease
lo be 8 member, such amount a8 may be requi￿d, not exceeding £1, for the dèb18 and liabilities
contracted before they eeased lo be a member.
RELATED PAR TY TRANSACTIONS
In ils commitment lo advance the education regarding diabetes, European Diabelology 1$ primarily
supportive of the joumal Diabelologia and ils associated society, the European Association forthe study
of Diabetes IEASDI. This may be In the form of financial grants but also professional benevolence.
EASD is the charity's primary benef￿lary and the charity ￿maInS open lo a$$i$ting ils various outreach
Inrtialiveg.
OBJECTIVES AND ACTIVITIES
The chanly's obiecls are specificalty reslricled to advancin9 the education of the public in general land
particularly among scienlisls and he81thcare prolessionalsl on the subieel of diabetology. This is lo be
achieved by, bul not limited to, the promotion of research for the public benefit in all aspects of that
subject and lo publish the useful resuf(s. In this year, the charity supported the EASD'S Young Academy
with a grant, enablin9 20 applicants lo lake a place on ils new Early Career Mentorship programme. 11
also took an active role in the ongoing negotiation ol Diabetologia's contract with publisher Springer
Natu￿, with the aim of best seNing ils staff, 8ulhory and readership in view of the Charity objecl.

European Diabetology
(A company limited by guarantee)
TRUSTEES. REPORT
The Trustees confim that they have complied with the duty in section 4 of the Charilie¥ Act 2011 to
have due rggard lo public benefit guidance published by the Charity Commission,
ACHIEVEMENTS AND PERFORMANCE
The charity has supported the advancement of education on the Bubjecl of diabetes by 5UPPOrting the
publication of the journal Diabelologi8 and the webs118 Diapedia, in particular by funding their editorial
aclivilies.
The Tru51ees have referred lo the guidance contained in the Charity Commission's general guidance
on public benefit when reviewing the aims and objectives and in planning the future 8clivilies of the
Charity.
FINANCIAL REVIEW
To181 income for the financi81 year was £702,711 12022.. £644,149>. Oulgoings and other gainsllosses
for the same yearwere £939,91912022. £4S3,7291 creating an annual dehcrt of £237,20812022.' SUfpIu3
£190,420>. Total funds carried forward into the new linancial year 8re £1,170,41512022.. £1.407,6231.
INVESTMENT POLICY
During the year, the ¢harily maintained a multi-assel fund with Schrod8rs. As the charrty's Inveslmonl
advisors, they ar& instructed to inve811o maximise 10181 relum within the con5trainls of a lower level fisk
portfolio. The investment brief is broadly defined, bul investments in compan￿5 that have positive
sccial, environment and ethical con$id¢ralions are held or pursued.
RESERVES
The Trustees examined the requirementa for free res9￿83 in November 2023 8nd agreed that, given
the natu￿ of the work and current oulslanding decisions on expenditure, this should bg approximately
£450,000. This includes the equivalent 016 months, running costs ol Diabelologia lo allow for an ordedy
wind-down of the aclivilies of the journal in the evenl of interruption of income from Springer. 11 also
provide8 8 conlingeney against changes in the terms agreed with the University of 8rislol in relation lo
the hosting ol Diabelologia. 11 also gives adequate working capital lo support quality improvement in
Diabelologi8. Therefore, the Trustee8 have decided 10 8armark £450,000 lo a separate designated fund
for clarity within thè Iinancial slalgmenls. The reserves as of 31 Augu812023 are £1,170,415 {2022.'
£1,407,623)
PLANS FOR FUTURE PERIODS
The charity plans lo continue 8UPPOrting the activities of Di8betologia and to fund new inilialives that
setve lo develop diabetes educalion in the scientific, medical and wider community as well as improve
the quality of the journal's output and marketing, when finances permit.
RISK MANAGEMENT
The Trustees consider the main risk lo the future of the charity lo be the funding provided, wilhoul this
the charity would not be able to provide support for the publication ol the journal Diabelologia. The
Trustees have a publishing agreement in place with Springer Nature lo receive royalties annually and
work closely with EASD and the jDurnal's Edilor-in-chief lo ensure Ihe financial forecast is secured.
THIRD PARTY INDEMNITY PROVISION FOR TRUSTEES
Qualrfying third party indemnity provision is in place for the benefit of all Trustees of the charitable
company.

European Diabetology
(A company limited by guarantee)
TRUSTEES, REPORT
SMALL COMPANY PROVISIONS
Th18 report has been prepared in accordance with the provisions 8pplicable lo compani98 8nlilled to
the small companie8. exempli(Jn.
On behalf of the board of Tru8tse8
Prof M K Rutter
TRUSTEE
Date,.
H 22, 2cJl

European Diabetology
(A company limited by guarantee)
STATEMENT OF TRUSTEES, RESPONSIBILITIES
The Trustees (who are also the directors of European Diabelology for the purposes of company law)
are responsible for preparing the Trustees, Annual Report and the financial slalemgnt5 in accordance
with appluble law and Untled Kingdom Accounting Standards (United Kingdom Generally Accepted
Accounting Praclicel.
Company law requires the Trustees lo prepare finan¢io1 $lalemenls lor each financial year which give
true and fair view of the stale of affairs of the Charitable company and of the income and expenditure
of the charitable company for that period. In p￿paring these financial slalemenls, the Trustees are
required to..
select ¥uilobb aGcounling policies and then appty them con8islenlly',
obsetve the method8 and principles in the Charities SORP.,
make judgment8 8nd accounting estimates Ihal are reasonable and prudent.,
slate whether applicable UK accounting standards have been followed, subject lo any malerial
departures di8closed and exp18ined in the financial slalemenls., and
p￿pare the financial Statements on the going concern basis unless il li Inappropri8le lo
presume that the charitable company will ¢onlirnue in business.
The Trusteès are r&spon$ible for keepin9 proper accounting record8 that disclose with reasonable
accuracy al any time the financial position of the charrtable company and enable them to ensure that
the financial slalemenls comply with the Companies Act 2006. They are also responsible for
Safeguarding the assets of the Charitable company and hence taking re88onable steps for the
prevgnlion and detection of fraud and other irregularil*s.
The Trustee8 are responsible lor the mainl•nance and inlegrily of the corporate and financial
information included on the charitable company's website. Legislation in the United Kingdom goveTning
the pr¢paral*)n and di8seminalion of financial $lalemenl¥ may differ from legislalKJn in other
jurisdictions,

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF EUROPEAN
DIABETOLOGY
I report lo the Trustees on my examination of the financial 5ts1emenls of European Diabetolc•Jy for the
year ended 31 August 2023, which are sel out on pages 7 10 16.
Responslbllltles and ba818 of report
As the Trustees of the company land also ils directors for the purposes of company lawl you are
responsible for the preparalion ol ihe financial slalemenls in accordance with the requirements of the
Companies Act 20061'lhe 2006 Acl'l.
Having satisfied myself that the financial statements of the company aw not required lo be audited
under Part 16 of the 2006 Act and are eligible for independent examination, I ￿pOrt in respect of my
8xaminalion of your charity's financial statemen15 as carried out under section 145 of the Charities Act
20111'lhe 2011 A¢l'l. In earrying out my exarninalion I have followed tho directions given by the Charity
Ctsrnmission under section 14515llbl of the 2011 Act.
An independent examination does not invO￿e gathering all the evidence that would be required in an
audit and consequently does not cover all the mallers that an auditor considers in giving their opinion
on the financial slalemenls. The planning and conduct of an audit goes beyond the limited assurance
that an independent examination can prOv￿e. Consequently, l express no opinion a$ lo whether the
financial 9talement3 present a 'lrue and lair view, and my report is limited lo Ihose specific mallers set
out in the independent examinerf8 slalemenl,
Indepondènt examlner's 8tstom8nt
Since the compony's gross income exceeded £250,000 your examiner musl be a m•mbgr of a body
listed in section 145 of the 2011 Act. I confim that l am qualified to undertake the examination because
l am a member of The Inslilule of Chartered Accounlanls In England and Wales, which is one of the
listed bodie8.
I have completed my ex8min81ion. I confim that no molerial mallers have come lo my allenlion in
connection with the gxaminalign giving me reasonable cause lo believe that in any material respect,.
accounting records were not kept in re8pecl of the company as requirod by section 386 01 the
20CÉ Act., or
tha financial $tatemtrn15 do not accord with those records., or
the lin8ncial 81alements do not comply with the accounting requirements of section 396 of the
2006 Act other than any raquiremènl that the accounts give a 'true and fair view, which is not a
matter Considered as part of an independent examination". or
the financial stal8menls have not been prepared in accordance with the methodg 8nd Pfineiples
of the Slalemenl of Recommended Praclic8'. Accounting and Reporting by Charities applicable
lo charities preparing their financial slal8menl in accordance with the Financial Reporting
Standard applicable in the UK and Ireland IFRS 1021.
I have no concern5 and have come across no other mallers in connection with the examination lo which
attention should be drawn in this report in order lo enable a proper understanding ol the financial
slalemenls lo be reached.
KERRY GALLAGHER FCA
The Institute of Chartered Accountants in England and Wales
Chartered Accountant
ON BEHALF OF RSM UK TAXAND ACCOUNTING LIMITED
Charter8d Accounlanls
Davidson House
The Forbury
Reading
RG1 3EU
Dale. 23105124

European Diabetology
(A company limited by guarantee)
UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES
(including an Incom8 and Expenditure Account)
for the year ended 31 Au
U812023
Unreslricled
funds
Total
funds
Totsl
funds
2023
2023
2022
INCOME FROM.
Note
Chorilable activities
Investments
682.931
19,780
682.931
19.780
625,401
18,748
TOTAL
702,711
702,711
644,149
EXPENDITURE ON..
Charrtable activities
1908,8751 1908,875)
1445,1281
TOTAL
1908,8751 1909,2551
1445,1281
Nel bsses on inve81m8nt8
131,0441
<31,0441
{8,8011
NET IEXPENDITUREIIINCOME AND NET
MOVEMENT IN FUNDS
1237,2081 1237,2081
190,420
RECONCILIATION OF FUNDS
Tol81 funds brought fotward 811 September
1,407,623
1.407,623
1.217,203
TOTAL FUNDS CARRIED FORWARD AT 31
AUGUST
13
1,170,41 S
1,170,415
1,407,623
All adivilies are cla88ed a8 continuing and w•re unrestncled in the current and prev￿u5 year.

Company Registration No. 08652560
European Diabetology
(A company limited by guarantee)
UNAUDITED BALANCE SHEET
as al 31 Augu512023
2023
2022
FIXED ASSETS
Inveslmants
506,240
517,504
506,240
517,504
CURRENT ASSETS
Debtors
Cash al bank and in
hand
10
294
932,650
329
1,319,442
932,944
1,319,771
CREDITORS..
Amounts falling due
within one year
1268.7691
1429,6521
NET CURRENT
ASSETS
664.175
890,119
NET ASSETS
1,170.415
1,407,623
FUNDS..
Unr¢$lri¢led fund8
Designated funds
13
13
720,415
450,000
957,623
450,000
1.170,415
1,407,623
For the year ended 31 August 2023, the company was entitled to exemption from audit under $ecli¢n
477 of the Companio$ Acl 2006 relating lo sm811 companie8 and Ils members have nol required the
company lo have 8n audit of ils financial slalemenl$ for the period in question in accordance with section
476.
The directors acknowledge their respon8ibililies for complying with the rgquiremenls of the Act with
respect to accounting records and the preparation of financial Slalements.
These financiol slalemenl8 have been prepared in 8¢¢ordgnce with the provisions applicable lo
companies subject lo the small companies, regime.
The fi'nancial Stslemenls on pages 7 10 16 were approved and authorisod for issue by Ihg officers on
and signed on their behalf by..
TRUSTEE

European Diabetology
(A company limited by guarantee)
UNAUDITED STATEMENT OF CASHFLOWS
For thfj year ended 31 August 2023
Notes
2023
2022
Cash lused inllprovided by operating a¢livilies
15
1386,7921
444,539
Change in cash in the year
1386,792)
444,539
Tol81 cash brought fopward
1,319,442
874,903
Total cash carried foNard
932,650
1,319,442

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023
ACCOUNTING POLICIES
CHARITY INFORMATION
European Diabelology is a private company limited by guarantee and incorporated in England and
Wales The registe￿d office is Fltrjr, 1 The Square, Temple Quay, Bristol, BS16DG.
European Diabelology meets the definition of a public benefit entity under sectlon 34 of FRS 102.
The princip81 objectives of the charrty are dgtailed in the Tru8lees' report on page 2 of Ihesefinancial
slalements.
The charity is a company limf(ed by guarantee. The members of the company are the Iru8lees
named on page 1. In the event of the charity being wound up. the liability in respect of the
guarantee is limited to £1 per member of the enlily.
ACCOUNTING CONVENTION
The a￿9￿￿1$ have been prepaT8d in accordance with the Slalernenl of Recommended Practice.,
A¢¢ounling antj Reporting by ch9r￿lleg preparing their accounts in accordance with the Financial
Reporting Standard applicable In the UK and Republic of Ireland IFRS 1021 second edition
October 2019 and Financial Reporting Standard applicable in Ihe United Kingdom and Republic
ol Ireland IFRS 1021 and the Companies Act 2006. The a￿OuntIng policigs as disclosed have
been 8pplied consislenlly throughout the currenl and preceding year.
The accounts are prepared under the historical ¢osl convention with the exception of fixed a88et
investments which are held at lair value.
The financial staiemenls presented in 8lerling which 18 Ihe functional currency ol the Gompany.
Monotary amounts in Ihe$e financial 8lalemen18 are rounded lo the neaffjsl £.
GOING CONCERN
The Iruslees have reviewed the expected cash outflows for the rhorily og¥in81 gxpecled cash
inflows and asset8 held for 12 months from the approval gf these financial slalemenls. The
Iruslees consider that there are no material uncertainties about the charity's ability lo continuo 85
a going concorn. and therefore have concluded that il is appropriate lo use the going concern
basis In the preparation of these accounts.
FUND ACCOUNTING
Unrestricted funds are available for USB at the discretion of the trustees in furtherance of thè
general obieclivg5 of the Charity and have not been reslricled for othèr purposes. Designalod
lunds are sel aside by the Iruslee8 to be spent on specrfic purpos95 as ils own discretion. The
deS￿nated funds currently in the financial slalemenls relate lo approximately 6 months, running
costs of Diabelologia.
INCOME
Income from charrtable activrties Is recogni5ed when the charity is enlilled lo Ihe income, it 18
Probab￿ that the inc(xne will be r￿1ved, and the anw)unl of income can be measured reliably.
Investsnent income is accounted for in the accounting period in which il is receivable.

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2C123
ACCOUNTING POLICIES ICONTINUEDI
EXPENDITURE
Liabilrties are recognised as resources expended as soon as there is a legal or eonslruclive
obligat￿n commilling the charity lo the expendrture. All expenditure Is 8ccounled for on an accruals
basis and has been classified under heatJing5 that aggregate all costs related lo the category.
Charitable expendrtuw comprises costs incurred by thé charity in delivery ol ils activities and
objective8. It includes both costs directly 811ribulgble lo aclivilies ond indirect costs neces8ary lo
support them.
Governance costs include Ihc6e costs a88ocialed wrth meeting the con$lilutional and slalulory
requirements of the charity and include independent examination fees and costs linked lo the
strategic management ol Ihe charity.
GAINS AND LOSSES
All gains and losses are laken lo the statement of financial activities a8 they 8rise. Realised gain8
ond losses on investments are calculated as the difference be￿&¢n sales proceed5 and their
opening carrying value orlheir purchase value if acquired subsequent lo the first day of the financial
year.
Unre81ised gains and losses a￿ c81culaled as tha difference be￿e8￿ the fair value al the year end
and their carry1ng value. R¢alisgd ond unrealised Inveslmenl gains and108se8 are combined in the
slalemenl of financial activities.
INVESTMENTS
Investments are a fomi of basic financial instrument and are initially measured at their Ir8nsaction
value and subsequently mèasured al their fair valuè as al the balan¢e sheet dole using the closing
quole(I price. The statement ol financial aclivilieg inGludfjs Iho nel gains and losses arising on
revaluation and disposals throughout the year.
The market value of investrnenls held in the portfelios are reprosenled within unr8stricl8d fund8
and the Income portfolio is included within the unreslricled di8lribulion fund accordingly.
FINANCIAL INSTRUMENTS
As the chanly only has basic financial inslrumenls, il has elected lo apply the provi8ion8 of Section
11 'Basic Finanei81 Inglrumenls. of FRS 102, to all ol ils financial instrurnenls.
Financial instruments are recognised when the charity becomes party to the contractual provislons
of the inslrumenl.
Financial assets and IBbilrties areoffset, with the nel amounts presented in the financial stalemenl5,
when there is a legally enforceable right10 Sel off the recognised amounts and there Is an intention
10 8ettk on 8 net basis or to realise the asset and settb the liability simultaneously.
Basio finanGial assets
Basic fi'nancial assets, which include other debtors and cash and bank balances, are rneasu￿d at
transaction price including transaction costs.
Classificat￿n of financial I18￿.111￿S
Financial liabilities and equrty instruments are classified according to the Substan￿ of the
onlractual arrangements entered into. An equity Instrument is any contract that evidences a
resKlual interest in the 855ets of the charity after deducting all of its Iiabilrties.
11

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCNL STATEMENTS
for the year ending 31 August 2023
ACCOUNTING POLICIES (CONTINUED}
Basic financial liab￿11￿$
Bas￿ financial liabilities, including accruals are recctyJni$ed al transactv)n price.
TAK4TION
The charity meets the delinrtion of a charrtable company for UK corporation tax purp08e8.
Accordingly. the charity 18 partially exempt from taxation in respect of income or capital gains lo the
extent that such income or gains arg applied exclusively lo charitablé purposes.
FOREIGN CURRENCIES
Assets and liabilrties in foroign currencies are translated into sterling al the rates ol exchange
ruling at the balance sheet dale. Transactions In forgign currencies are translated into sterling al
the r8le of exchange wling al the dale of the transaction. Exchange differenees arè taken into
account in arriving al the nel Income for the year.
INCOME FROM CHARITA8LE ACTIVITIES
Unffj$lri¢t•d
fund8
Total
funds
Total
funds
2023
2023
2022
Promotion of medical research
882,931
682,931
825,401
During the current and prior year, all the income from charitable activitie8 was ￿ceIVed from
markets outside the UK bul wrthin Europ¢
INCOME FROM INVESTMENTS
Unreslricled
fund8
Tot81
funds
Total
funds
2023
2023
2022
Dividend income
19,780
19,780
18,748
12

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023
ANALYSIS OF CHARITABLE EXPENDITURE
Unreslrieled Unrestricted
funds
funds
Aclivilie5
Support
undertaken
C0818
directly
(Note 51
Total
lund$
Total
fvnds
2023
2023
2023
2022
Promotion of medical re8èafch
897,869
11,006
908,875
445,128
897,869
11,008
908,875
445,128
The promotion ol Fnedical research cos18 in the year Includes £422,358 of costs relating lo the
year ended 31 Augu812022 which have nol been reflected in the linancNI slalemenls for that year.
ALLOCATION OF SUPPOR T AND GOVERMANCE COSTS
Support Govem8nce
CO818
C0818
Total
Total
2023
2023
2023
2022
Accountancy cost8
Bank charges
Independent examinallon fee8
8,108
748
8.108
748
2,150
e.855
18
1,280
2,150
8,856
2,150
11,OC6
10,151
RECOGNISED GAINSIILOSSESI
Unre$lricted
fvnds
Total
funds
Total
funds
2023
2023
2022
Unrealised gainslllo88es} on inve8lment8 Inole 91
131.0441
131,0441
18,8011
131.0441
131,0441
18,6011
TRUSTEES
The Trustees neither re￿iVed nor waived any emoluments from the charity during Ihe year12022..
£nill. No Trustees receive(I paymenls12022." nil) in respect of travel ¢0$15 reimbursed. The Trustees
are considered to be the key management personnel of the chanty.
13

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 Augu$l 2023
EMPLOYEES
European Diabetology has no employegs. The pgrsonnel areempbyed by The Univ8r8ty of Bristol,
who recharge these costs lo th& charity.
INVESTMENTS
2023
2022
Valuation al 1 September
Additions
Unrealised108s on inveslmanls
517,504
19.780
131,044}
507,357
18,748
18,6011
Valuation al 31 Augu81
506,240
517,504
Th• ¢hority hold8 invgslments in a multl-888et fund with Schroders.
10 DEBTORS
2023
2022
Prepayments
Other debtors
158
136
210
119
294
329
11
CREDITORS.. Amoun18 falling Llue wrthin one year
2023
2022
Accruals gnd deferred income
268,769
429,652
288,769
429,652
Included in the above is £23S,30012022.. £211,17910l deferred income. This is in relation to the
remaining annual amount due from the publishing agreement. All deferred income from 2022 has
boen released to the statement of finanual acliwtie$ In the Cu￿nI year.
12 FINANCIAL INSTRUMENTS
2023
2022
Equity instruments measured al fair value
506,240
517.504
14

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUDITED FINANCIAL STATEMENTS
for the year ending 31 August 2023
13 MOVEMENTS IN FUNDS
Nel gainsl
1108sesl on
Income Expenditure investrnonts
A131
August
2023
Ali
September
2022
Unfftslricled fund5
Oesignated funds
957.623
450,000
702,711
1908,8751
{31,0441
720,415
450,000
1,407,623
702,711
(908,8751
131,0441 1.170,415
Nel gain81
Ilossesl on
Income Expenditure investments
A131
August
2022
A11
Septemb•r
2021
Unwslricled funds
De$ign4led lunds
767,203
450,000
844,149
1448.1281
18,6011
957,623
450,000
1.217.203
644.149
1448.1281
18,6011 1,407,823
No reslricled fund8 were received In tho year.
The Trustees have decitjed lo ¢Jesign8le approximately 6 months, running costs of Diabelologia.
Thi8 would albw for an orderly wind-down ol the activities of the iournal in the event of interruption
of income from Springer. The fund8 remain unreslncted and c8n be 8penl al the Trustees,
di8Cf81ion.
14
ANALYSIS OF NET ASSETS 8ErnEEN FUNDS
Total
Total
Unreslricled Unrg8lricled
Funds
Fund8
Year ended
31 August
2023
Year ended
31 August
2022
Fund b81ances al 31 August are repre88nled by..
Fixed assets
Current assets
Cfftdilors.. arnounls falling due within one year
5C6,240
932,944
1268,7691
517,504
1.319,771
1429,6521
1.170,415
1.407,623
15

European Diabetology
(A company limited by guarantee)
NOTES TO THE UNAUOITEO FINANCIAL STATEMENTS
for the year ending 31 August 2023
15
RECONCILIATION OF NET IEXPENDITUREIANCOME TO NET CASHFLOW FROM
OPERATING ACTIVITIES
2023
2022
Net {expendilurellincome
Loss on inveslmenl$
Dividends from investments
Oe¢rease in debtors
1237,2081
31,044
119.7801
35
190,420
8,601
118,7481
1C6,171
IDecre8$ellin¢rease in credito
1160,8831
158,095
Nel cash lused inyprovided by oporaling activrti88
1386,7921
444.539
16
ANALYSIS OF CHANGES IN NET FUNDS
A131
August
2022
A131
August
2023
Cash
flows
Cash at bank and in hand
1,319,442
1386,7921
932,650
1,319,442
1386,792)
923,650
17
RELATED PARTIES
The University of 8ri8101 are the empkiyer of Some of the tru8lee8 of Europèan Diabotology.
Expenses of £898,075 were incurred in relation lo the University of Bristol during the year12022.
£460,062>. No inlerèsl 15 due il payment 18 received 30 days from the ￿nvo￿8 dale. The following
ba18nce 8he$l rtems relate lo amounts du6 lol from the University of Bristol.
2023
2022
AccnJal$
26,397
211,179
16